Centene Corporation CNC

equity

Price History

2001-12 · DCA start$1.83

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

2001-122026-08 · -27.9%

Worst drawdown: −72%, peaking Jul 2022 and bottoming Jul 2025 — still unrecovered after 49 months.

DCA Backtest

Start month

Monthly amount (USD)

Invested: $29,700
Value today: $221,318
Return: +645.2%
Months invested: 297

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $42,254 today, so the real (inflation-adjusted) return is +423.8%.

Lump sum instead — $29,700 all at once in Dec 2001: $1,089,009 (+3566.7%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Jul 2022): $5,732 on $5,000 invested (+14.6%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

	J	F	M	A	M	J	J	A	S	O	N	D
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2001-12: +645.2%

About Centene Corporation

Centene Corporation is an American for-profit healthcare company that serves as an intermediary for government-sponsored and privately insured healthcare programs. Based in Clayton, Missouri, Centene ranked No. 23 on the 2025 Fortune 500. (Wikipedia)

It's a listed company categorised under health care and managed health care, with a market cap of about $33.1B.

It rates High Risk at 3.2/5, meaning several rated factors score badly, so this carries materially more risk than a typical holding.

What pushes the score up: earnings quality (5.0/5) and market / volatility (3.7/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

High Risk(3.2/5)80% rated

How these ratings work

Market / Volatility3.7/5 · weight 20%

Annualised volatility (3yr)5/561.1
Max drawdown from ATH4/572.0
Beta vs S&P 5002/50.79

Liquidity1.0/5 · weight 15%

Avg daily $ volume1/5330.3m
Float % of shares outstandingnot yet researched

Leverage / Financial3.0/5 · weight 20%

Debt / equity3/50.71
Interest coverage (EBIT / interest)not yet researched

Earnings Quality5.0/5 · weight 15%

3yr EPS volatility5/5100

Concentrationunrated · weight 10%

Largest customer, % of revenuenot yet researched
Geographic revenue concentrationnot yet researched

Governanceunrated · weight 10%

Board independence %not yet researched
Share structurenot yet researched
Litigation / audit historynot yet researched

Sector / Regulatory3.0/5 · weight 10%

Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.